March 1, 2012

Helix BioPharma Corp. announces L-DOS47 Scientific Presentation to be made at the Second Annual IBC Conference on Analytical Technologies Biotherapeutic Development (PDF)

AURORA, Ontario, March 01, 2012 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical
company developing drug candidates for the prevention and treatment of cancer, today announced that an L-DOS47 scientific
presentation will be made at the Second Annual IBC Conference on Analytical Technologies Biotherapeutic Development in
San Diego California USA.